Any Solid Tumor
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations (NCT04521686) | Eli Lilly and Company | 2020-10-01 |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (NCT03157128) | Eli Lilly and Company | 2017-05-02 |
Track Any Solid Tumor automatically
Every clearance here is in the API, with alerts when new ones post.